| ID: | 173 | |
|---|---|---|
| Name: | Compound 173 | |
| Description: | Original numeration in publication: 13 | |
| Labels: | Test_set, Thiazolidine-2, 4-dione | |
| CAS: | ||
| InChi Code: | InChI=1S/C21H17Cl2N3O4S/c1-2-24-19(28)12-4-7-15(8-5-12)25-18(27)11-26-20(29)17(31-21(26)30)9-13-3-6-14(22)10-16(13)23/h3-10H,2,11H2,1H3,(H,24,28)(H,25,27)/b17-9- |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.64 |
El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. A., R. R.; Mahdy, H. A.; Nasser, M. a. A., H. S.; El-Hddad, S. S. A. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000279. https://doi.org/10.1002/ardp.202000279 |
| 6.31533 |
Eq1: VEGFR-2 inhibition (Data used to validate model) |